Positive results from the Phase 2-3 COVA study presented at the 21st ERS 2023 Lung Science Conference

.Biophytis announced that it presents the positive results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 at the European Respiratory Society 2023 21st Lung Science Conference taking place in Estoril, Portugal, between the 9th and the 12th of March 2023.

Professor Suzana Lobo, MD – Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto, São Paulo, Brazil and Investigator of the COVA study in Brazil, will be holding an oral presentation of the results titled “COVA clinical study: Results from a double-blind, placebo-controlled phase 2/3 study to assess efficacy and safety of BIO101 in hospitalized severe COVID-19 patients.”

Biophytis will also present a poster that will be available on Biophytis’ website after the conference.

The ERS Lung Science Conference (LSC) is at the forefront of basic and translational respiratory science and is an essential event for all respiratory researchers. It offers a unique opportunity to present the results in front of well-recognized peers from across the globe.

Stanislas Veillet, CEO of Biophytis, said: “We are very excited to present these positive data to the scientific community. This huge success is the result of Biophytis scientific excellence and hard work of the clinical and medical teams involved in the COVA clinical study in France, Belgium, the USA and in Brazil. Sarconeos (BIO101) is the only innovative drug candidate in Europe or the United States directly targeting respiratory failure that has demonstrated clinical efficacy in hospitalized patients with hypoxemia caused by COVID-19 as well as a very good safety profile. We are looking forward to the interactions with the scientists from around the world attending this conference.”